TD Asset Management
ACHN

TD Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

TD Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-208,587
Closed -$768K – 1460
2018
Q3 		$768K Buy
208,587
+3,100
+2% +$9.24K ﹤0.01% 1211
2018
Q2 		$582K Buy
205,487
+2,200
+1% +$7.49K ﹤0.01% 1239
2018
Q1 		$754K Buy
+203,287
New +$665K ﹤0.01% 1124
2016
Q4 		– Sell
-77,208
Closed -$625K – 1416
2016
Q3 		$625K Sell
77,208
-67,400
-47% -$573K ﹤0.01% 1116
2016
Q2 		$1.13M Buy
144,608
+1,508
+1% +$12.9K ﹤0.01% 944
2016
Q1 		$1.1M Buy
143,100
+18,500
+15% +$135K ﹤0.01% 944
2015
Q4 		$1.34M Sell
124,600
-2,100
-2% -$19.1K ﹤0.01% 894
2015
Q3 		$875K Buy
+126,700
New +$1.03M ﹤0.01% 949
2013
Q3 		– Sell
-45,400
Closed -$371K – 1283
2013
Q2 		$371K Buy
+45,400
New +$347K ﹤0.01% 992

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

TD Asset Management's ACHN Position: Q4 2018 in Review

TD Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q4 2018, closing a stake of 208,587 shares — an estimated $768K sold.

TD Asset Management first reported a position in ACHN in Q2 2013 and held it in 9 quarters. The position peaked at $1.34M in Q4 2015. 121 funds tracked by Wall St. Rank hold ACHN as of Q4 2018.

  • TD Asset Management reported no remaining Achillion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • TD Asset Management sold 208,587 Achillion Pharmaceuticals shares in Q4 2018, an estimated $768K.
  • TD Asset Management first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 9 quarters.
  • TD Asset Management's Achillion Pharmaceuticals position peaked at $1.34M in Q4 2015.
  • 121 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2018.

Based on TD Asset Management's 13F filing for Q4 2018, filed 1 Feb 2019.